Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

ABSTRACT Introduction Opaganib is a first‐in‐class oral sphingolipid metabolism inhibitor that inhibits sphingosinekinase 2 (SphK2) and dihydroceramide desaturase (DES) and that has a demonstrated safety and preliminary anti‐cancer activity signal in a Phase I study. Methods In this phase II trial,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jacqueline T. Brown, Bassel Nazha, Anna C. Ferreira, Kent Armeson, Elizabeth G. Hill, Besim Ogretmen, Shikhar Mehrotra, Alan Brisendine, George Magrath, Terry F. Plasse, Theodore Stewart Gourdin, Omer Kucuk, Michael Lilly
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-04-01
Col·lecció:	Cancer Medicine
Matèries:	abiraterone enzalutamide opaganib prostate cancer sphingolipid
Accés en línia:	https://doi.org/10.1002/cam4.71633
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!